한국간담췌외과학회지 (Annals of Hepato-Biliary-Pancreatic Surgery)

  • 제28권2호
  • /
  • Pages.248-261
  • /
  • 2024
  • /
  • 2508-5778(pISSN)
  • /
  • 2508-5859(eISSN)
한국간담췌외과학회 (The Korean Association of Hepato-Biliary-Pancreatic Surgery)
권호 표지
DOI QR코드

DOI QR Code

Prognostication for recurrence patterns after curative resection for pancreatic ductal adenocarcinoma

  • Andrew Ang (The Royal London Hospital, Barts Health NHS Trust) ;
  • Athena Michaelides (The Royal London Hospital, Barts Health NHS Trust) ;
  • Claude Chelala (Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre) ;
  • Dayem Ullah (Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre) ;
  • Hemant M. Kocher (The Royal London Hospital, Barts Health NHS Trust)
  • 투고 : 2023.11.15
  • 심사 : 2024.02.10
  • 발행 : 2024.05.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Backgrounds/Aims: This study aimed to investigate patterns and factors affecting recurrence after curative resection for pancreatic ductal adenocarcinoma (PDAC). Methods: Consecutive patients who underwent curative resection for PDAC (2011-21) and consented to data and tissue collection (Barts Pancreas Tissue Bank) were followed up until May 2023. Clinico-pathological variables were analysed using Cox proportional hazards model. Results: Of 91 people (42 males [46%]; median age, 71 years [range, 43-86 years]) with a median follow-up of 51 months (95% confidence intervals [CIs], 40-61 months), the recurrence rate was 72.5% (n = 66; 12 loco-regional alone, 11 liver alone, 5 lung alone, 3 peritoneal alone, 29 simultaneous loco-regional and distant metastases, and 6 multi-focal distant metastases at first recurrence diagnosis). The median time to recurrence was 8.5 months (95% CI, 6.6-10.5 months). Median survival after recurrence was 5.8 months (95% CI, 4.2-7.3 months). Stratification by recurrence location revealed significant differences in time to recurrence between loco-regional only recurrence (median, 13.6 months; 95% CI, 11.7-15.5 months) and simultaneous loco-regional with distant recurrence (median, 7.5 months; 95% CI, 4.6-10.4 months; p = 0.02, pairwise log-rank test). Significant predictors for recurrence were systemic inflammation index (SII) ≥ 500 (hazard ratio [HR], 4.5; 95% CI, 1.4-14.3), lymph node ratio ≥ 0.33 (HR, 2.8; 95% CI, 1.4-5.8), and adjuvant chemotherapy (HR, 0.4; 95% CI, 0.2-0.7). Conclusions: Timing to loco-regional only recurrence was significantly longer than simultaneous loco-regional with distant recurrence. Significant predictors for recurrence were SII, lymph node ration, and adjuvant chemotherapy.

키워드

과제정보

Barts Pancreas Tissue Bank is funded by Pancreatic Cancer Research Fund. The Operations Group is chaired by Prof Hemant Kocher/Prof Claude Chelala and Tissue Access Committee by Professor Richard Grose. Vickna Balarajah, Abhirup Banerjee, Mafalda CostaNeves, Konstantinos Stasinos, Mohamed Zardab, Andreas Konstantinou helped with clinical verification of data collection. Past members helping in running of Barts Pancreas Tissue Bank include, Archana Ambily, Thomas Dowe, Ajith Vajrala, and Ope Banwo. We are grateful to consultant surgeons at Barts: Satyajit Bhattacharya, Robert Hutchins, Ajit Abraham, Vincent Yip, Deepak Hariharan, Omar Mowanah for access to their patients. We are grateful to Dr Joanne Chin-Aleong, Consultant Pathologist and Dr David Propper/Dr Sarah Slater, Consultant Oncologist for their valuable advice.

참고문헌

  1. Carioli G, Malvezzi M, Bertuccio P, Boffetta P, Levi F, La Vecchia C, et al. European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer. Ann Oncol 2021;32:478-487. https://doi.org/10.1016/j.annonc.2021.01.006
  2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012: Estimated Cancer Incidence and Mortality Worldwide in 2012 v1.0: IARC cancerbase No. 11. International Agency for Research on Cancer, 2012.
  3. Eliison LF, Wilkins K. An update on cancer survival. Heal Rep 2010;21:55-60.
  4. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goere D, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26 Suppl 5:v56-68. https://doi.org/10.1093/annonc/mdv295
  5. Jones RP, Psarelli EE, Jackson R, Ghaneh P, Halloran CM, Palmer DH, et al. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial. JAMA Surg 2019;154:1038-1048. https://doi.org/10.1001/jamasurg.2019.3337
  6. Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol 2022;8:1571-1578. https://doi.org/10.1001/jamaoncol.2022.3829
  7. Kalisvaart M, Broadhurst D, Marcon F, Pande R, Schlegel A, Sutcliffe R, et al. Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study. HPB (Oxford) 2020;22:1240-1249. https://doi.org/10.1016/j.hpb.2020.01.005
  8. Tanaka M, Mihaljevic AL, Probst P, Heckler M, Klaiber U, Heger U, et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br J Surg 2019;106:1590-1601. https://doi.org/10.1002/bjs.11295
  9. Hayashi K, Ono Y, Takamatsu M, Oba A, Ito H, Sato T, et al. Prediction of recurrence pattern of pancreatic cancer post-pancreatic surgery using histology-based supervised machine learning algorithms: a single-center retrospective study. Ann Surg Oncol 2022;29:4624-4634. https://doi.org/10.1245/s10434-022-11471-x
  10. Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg 2018;267:936-945. https://doi.org/10.1097/SLA.0000000000002234
  11. Watanabe Y, Nishihara K, Niina Y, Kudo Y, Kurata K, Okayama T, et al. Patients with lung recurrence after curative resection for pancreatic ductal adenocarcinoma have a better prognosis than those with recurrence at other sites. JOP J Pancreas 2017;18:54-61.
  12. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-7259. https://doi.org/10.1158/1078-0432.CCR-04-0713
  13. Kim JH. Multicollinearity and misleading statistical results. Korean J Anesthesiol 2019;72:558-569. https://doi.org/10.4097/kja.19087
  14. Groot VP, Gemenetzis G, Blair AB, Ding D, Javed AA, Burkhart RA, et al. Implications of the pattern of disease recurrence on survival following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg Oncol 2018;25:2475-2483. https://doi.org/10.1245/s10434-018-6558-7
  15. Kolbeinsson H, Hoppe A, Bayat A, Kogelschatz B, Mbanugo C, Chung M, et al. Recurrence patterns and postrecurrence survival after curative intent resection for pancreatic ductal adenocarcinoma. Surgery 2021;169:649-654. https://doi.org/10.1016/j.surg.2020.06.042
  16. Kubo H, Ohgi K, Sugiura T, Ashida R, Yamada M, Otsuka S, et al. The association between neoadjuvant therapy and pathological outcomes in pancreatic cancer patients after resection: prognostic significance of microscopic venous invasion. Ann Surg Oncol 2022;29:4992-5002. https://doi.org/10.1245/s10434-022-11628-8
  17. Zheng B, Ohuchida K, Yan Z, Okumura T, Ohtsuka T, Nakamura M, et al. Primary recurrence in the lung is related to favorable prognosis in patients with pancreatic cancer and postoperative recurrence. World J Surg 2017;41:2858-2866. https://doi.org/10.1007/s00268-017-4068-6
  18. Ferguson MD, Dong L, Wan J, Deneve JL, Dickson PV, Behrman SW, et al. Molecular alterations associated with DNA repair in pancreatic adenocarcinoma are associated with sites of recurrence. J Gastrointest Cancer 2019;50:285-291. https://doi.org/10.1007/s12029-018-0073-8
  19. Shin SH, Kim HJ, Hwang DW, Lee JH, Song KB, Jun E, et al. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: a prospective cohort study. Oncotarget 2017;8:17945-17959. https://doi.org/10.18632/oncotarget.14901
  20. Ng KYY, Chow EWX, Jiang B, Lim C, Goh BKP, Lee SY, et al. Resected pancreatic adenocarcinoma: an Asian institution's experience. Cancer Rep 2021;4:e1393.
  21. Maggino L, Malleo G, Crippa S, Belfiori G, Nobile S, Gasparini G, et al. CA19.9 response and tumor size predict recurrence following post-neoadjuvant pancreatectomy in initially resectable and borderline resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol 2023;30:207-219. https://doi.org/10.1245/s10434-022-12622-w
  22. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012;148:362-375. https://doi.org/10.1016/j.cell.2011.11.060
  23. Barnes CA, Aldakkak M, Christians KK, Clarke CN, Dua K, George B, et al. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. Surgery 2020;168:440-447. https://doi.org/10.1016/j.surg.2020.04.031
  24. Park Y, Jun HR, Choi HW, Hwang DW, Lee JH, Song KB, et al. Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma. Sci Rep 2021;11:1644.
  25. Hugenschmidt H, Labori KJ, Borgen E, Brunborg C, Schirmer CB, Seeberg LT, et al. Preoperative CTC-detection by cellsearch® is associated with early distant metastasis and impaired survival in resected pancreatic cancer. Cancers 2021;13:485.
  26. Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 2016;388:248-257. https://doi.org/10.1016/S0140-6736(16)30583-9
  27. Hernandez JM, Morton CA, Al-Saadi S, Villadolid D, Cooper J, Bowers C, et al. The natural history of resected pancreatic cancer without adjuvant chemotherapy. Am Surg 2010;76:480-485. https://doi.org/10.1177/000313481007600514
  28. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006;10:511-518. https://doi.org/10.1016/j.gassur.2005.09.016
  29. Honselmann KC, Pergolini I, Castillo CF, Deshpande V, Ting D, Taylor MS, et al. Timing but not patterns of recurrence are different between node-negative and node-positive resected pancreatic cancer. Ann Surg 2020;272:357-365. https://doi.org/10.1097/SLA.0000000000003123
  30. Walston S, Salloum J, Grieco C, Wuthrick E, Diaz DA, Barney C, et al. Identifying clinical factors which predict for early failure patterns following resection for pancreatic adenocarcinoma in patients who received adjuvant chemotherapy without chemoradiation. Am J Clin Oncol 2018;41:1185-1192. https://doi.org/10.1097/COC.0000000000000452
  31. Suto H, Okano K, Oshima M, Ando Y, Takahashi S, Shibata T, et al. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy. BMC Surg 2019;19:186.
  32. Schorn S, Demir IE, Samm N, Scheufele F, Calavrezos L, Sargut M, et al. Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. BJS Open 2018;2:52-61. https://doi.org/10.1002/bjs5.46
  33. Zhou Q, Su S, You W, Wang T, Ren T, Zhu L. Systemic inflammation response index as a prognostic marker in cancer patients: a systematic review and meta-analysis of 38 cohorts. Dose Response 2021;19:15593258211064744.
  34. Cao W, Shao Y, Zou S, Wang N, Wang J. Prognostic significance of systemic immune-inflammation index in patients with bladder cancer: a systematic review and meta-analysis. Medicine (Baltimore) 2022;101:e30380.
  35. Liu XC, Jiang YP, Sun XG, Zhao JJ, Zhang LY, Jing X. Prognostic significance of the systemic immune-inflammation index in patients with cholangiocarcinoma: a meta-analysis. Front Oncol 2022;12:938549.
  36. Zhang K, Hua YQ, Wang D, Chen LY, Wu CJ, Chen Z, et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. J Transl Med 2019;17:30.
  37. Liu X, Sun X, Liu J, Kong P, Chen S, Zhan Y, et al. Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol 2015;8:339-345. https://doi.org/10.1016/j.tranon.2015.06.006
  38. Jomrich G, Gruber ES, Winkler D, Hollenstein M, Gnant M, Sahora K, et al. Systemic immune-inflammation index (SII) predicts poor survival in pancreatic cancer patients undergoing resection. J Gastrointest Surg 2020;24:610-618. https://doi.org/10.1007/s11605-019-04187-z
  39. Aziz MH, Sideras K, Aziz NA, Mauff K, Haen R, Roos D, et al. The systemic-immune-inf lammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study. Ann Surg 2019;270:139-146. https://doi.org/10.1097/SLA.0000000000002660
  40. Kim HJ, Lee WJ, Kang CM, Hwang HK, Bang SM, Song SY, et al. Risk factors associated with loco-regional failure after surgical resection in patients with resectable pancreatic cancer. PLoS One 2016;11:e0157196.
  41. Kwon J, Lee SR, Park SY, Lee JH, Song KB, Hwang DW, et al. Effect of resection margin status on recurrence pattern and survival in distal pancreatectomy for left-sided pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 2023;30:633-643. https://doi.org/10.1002/jhbp.1272
  42. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007;246:52-60. https://doi.org/10.1097/01.sla.0000259391.84304.2b
  43. Kurreck A, Weckwerth J, Modest DP, Striefler JK, Bahra M, Bischoff S, et al. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials. Eur J Cancer 2021;150:250-259. https://doi.org/10.1016/j.ejca.2021.03.036
  44. Tummers WS, Groen JV, Sibinga Mulder BG, Farina-Sarasqueta A, Morreau J, Putter H, et al. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Br J Surg 2019;106:1055-1065. https://doi.org/10.1002/bjs.11115
  45. Yamamoto T, Uchida Y, Terajima H. Clinical impact of margin status on survival and recurrence pattern after curative-intent surgery for pancreatic cancer. Asian J Surg 2019;42:93-99. https://doi.org/10.1016/j.asjsur.2017.09.003